Eli Lilly's (LLY) oral GLP-1 drug, orforglipron, met expectations in the phase 3 Achieve-1 trial for type 2 diabetes and reduced hemoglobin A1C with a weight loss of 16 pounds at the highest dose, Truist Securities said in a note on Thursday.
The firm said that the company plans to file for approval of the drug for obesity by year-end and for type two diabetes in 2026, with results of two major obesity focused trials expected in Q3.
Truist said that it does not expect Lilly to face the same supply constraints as current GLP-1 injectables when manufacturing orforglipron and global investments support the potential for a broad commercial launch.
The firm models peak global sales of orforglipron at about $14.7 billion, compared with a consensus estimate of $16.8 billion.
Truist reiterated its buy rating on Lilly's stock and kept the price target unchanged at $1,038.
Price: 828.95, Change: +94.05, Percent Change: +12.80
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。